Bionomics Limited
NASDAQ:BNOX
0.2531 (USD) • At close December 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 15 | 0.663 | 0 | 0 | 0.099 | 0.047 | 0.02 | 0.173 | 0 | 0.042 | 4.064 | 0.123 | 0 | 0.467 | 0.096 | 1.196 | 1.133 |
| Cost of Revenue
| 0 | 0 | 0 | 0.436 | 5.268 | 2.484 | 5.897 | 2.959 | 7.325 | 3.441 | 6.244 | 5.054 | 2.781 | 1.583 | 0 | 2.681 | 0 |
| Gross Profit
| 0 | 0.663 | 0 | -0.436 | -5.169 | -2.438 | -5.552 | -2.787 | -7.235 | -3.399 | -2.18 | -4.931 | -2.539 | -1.117 | 0.096 | -1.485 | 1.133 |
| Gross Profit Ratio
| 0 | 1 | 0 | 0 | -52.246 | -52.254 | -277.6 | -16.132 | 0 | -80.046 | -0.536 | -40.07 | 0 | -2.394 | 1 | -1.242 | 1 |
| Reseach & Development Expenses
| 1.616 | 1.737 | 1.901 | 1.111 | 2.035 | 2.484 | 8.85 | 2.959 | 10.76 | 3.441 | 6.244 | 5.054 | 3.71 | 1.583 | 1.317 | 2.681 | 0 |
| General & Administrative Expenses
| 1.407 | 2.629 | 1.667 | 0.317 | 2.518 | 2.379 | 3.034 | 1.523 | 2.778 | 1.305 | 1.907 | 3.369 | 1.71 | 1.614 | 0 | 1.423 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | -0.185 | 0 | 0.036 | 0.073 | 0.037 | 0.076 | 0.036 | 0.066 | 0.121 | 0.446 | 0.522 | 0 | 0.387 | 0 |
| SG&A
| 1.407 | 2.629 | 1.667 | 8,461.792 | 2.518 | 1.979 | 4.66 | 1.559 | 4.19 | 1.341 | 1.973 | 3.49 | 2.88 | 2.136 | 2.25 | 1.81 | 3.003 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 3.023 | 4.366 | 3.568 | 1.243 | 4.553 | 5.468 | 17.18 | 2.568 | 14.82 | 1.876 | 3.895 | 4.613 | 7.14 | 1.402 | 3.568 | 2.658 | 3.003 |
| Operating Income
| 11.977 | -3.704 | -3.568 | -1.679 | -4.553 | -5.468 | -17.16 | -4.346 | -14.82 | -4.739 | -4.153 | -8.416 | -7.14 | -3.174 | -3.471 | -3.295 | -1.87 |
| Operating Income Ratio
| 0.798 | -5.589 | 0 | 0 | -46.02 | -117.196 | -858 | -25.157 | 0 | -111.603 | -1.022 | -68.39 | 0 | -6.804 | -36.064 | -2.755 | -1.65 |
| Total Other Income Expenses Net
| -0.796 | 1.772 | 2.631 | 2,313.767 | -0.182 | -0.557 | -0.453 | -0.916 | 0.396 | -0.477 | -4.001 | -0.501 | -1.263 | 3.09 | 3.661 | -2.676 | 2.633 |
| Income Before Tax
| 11.181 | -1.932 | -0.937 | -0.036 | -4.589 | -5.507 | -15.74 | -5.262 | -16.31 | -5.216 | -6.077 | -9.554 | -8.78 | -0.084 | 0.19 | -4.635 | 0.763 |
| Income Before Tax Ratio
| 0.745 | -2.915 | 0 | 0 | -46.384 | -118.032 | -787 | -30.459 | 0 | -122.836 | -1.495 | -77.638 | 0 | -0.18 | 1.972 | -3.875 | 0.674 |
| Income Tax Expense
| 0.081 | 0.012 | -0.132 | 0.046 | -0.11 | -0.035 | -0.1 | 0.034 | -0.1 | 0.033 | 0.067 | 0.069 | -0.09 | 0.074 | -0.072 | 0.069 | -0.309 |
| Net Income
| 11.262 | -1.943 | -0.805 | -0.081 | -4.554 | -5.473 | -15.64 | -5.228 | -16.21 | -5.183 | -6.011 | -9.484 | -8.68 | -0.01 | -0.465 | -4.566 | 1.072 |
| Net Income Ratio
| 0.751 | -2.932 | 0 | 0 | -46.03 | -117.303 | -782 | -30.262 | 0 | -122.059 | -1.479 | -77.069 | 0 | -0.021 | -4.831 | -3.818 | 0.946 |
| EPS
| 189 | -221.4 | -0.61 | -1.8 | -145.08 | -146.19 | -159.84 | -158.1 | -194.4 | -192.6 | -83.72 | -210.6 | -139.15 | -0.28 | 20.88 | -189 | 64.8 |
| EPS Diluted
| 189 | -32.4 | -15.37 | -1.8 | -145.08 | -146.19 | -159.84 | -158.1 | -194.4 | -192.6 | -133.43 | -210.6 | -139.15 | -0.28 | 20.88 | -189 | 64.8 |
| EBITDA
| 11.977 | -3.231 | -3.402 | 0.401 | -4.292 | -5.302 | -10.959 | -4.191 | -11.005 | -4.591 | -10.355 | -9.724 | -6.441 | 0.424 | 0.847 | -3.745 | 1.348 |
| EBITDA Ratio
| 0.798 | -4.875 | 0 | 0 | -43.382 | -113.638 | -547.95 | -24.26 | 0 | -108.118 | -2.548 | -79.019 | 0 | 0.908 | 8.806 | -3.131 | 1.19 |